30
Participants
Start Date
June 27, 2023
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2026
Giredestrant
Participants will receive giredestrant 30 milligrams (mg) taken orally (PO) once a day (QD) on Days 1 to 28 of each 28-day cycle for 6 cycles. After completion of 6 cycles, the participant and investigator can choose to continue study treatment for an additional 18 cycles or discontinue study treatment and receive investigator-determined care.
Western Pennsylvania Hospital, Pittsburgh
Virginia Oncology Associates, Norfolk
Mount Sinai Medical Center, Miami Beach
Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS, Meldola
Minnesota Oncology Minneapolis, Minneapolis
University of Arkansas for Medical Sciences, Little Rock
Texas Oncology, P.A. - Fort Worth, Fort Worth
Englewood Health/Hematology Oncology Practice of Englewood (HOPE), Englewood
Jewish General Hospital, Montreal
McGill University Health Centre - Glen Site, Montreal
Narodowy Inst.Onkol.im.Sklodowskiej-Curie Panstw.Inst.Bad Gliwice, Gliwice
Swietokrzyskie Centrum Onkologii, Kielce
Hoffmann-La Roche
INDUSTRY